MAPK directs interactions between tumor cells and the surrounding T-cell infiltrate, downregulates T-cell co-stimulatory molecules, and suppresses the expression of negative immune checkpoints such as PD-L1 and CTLA4 in several cancers [37]. Here, CTLA4 is linked to cancer.